Oct 18, 2016


Metabolic Health – A Key Factor for Long-Term Health

Weight gain, poor dietary choices and a sedentary lifestyle are key predictors for long-term wellness and lead to metabolic health issues that potentially double the risk of heart disease and increase the risk of diabetes five-fold. Sixty-nine percent of adults over the age of 20 are overweight or obese and 80 percent of adults don’t get the recommended amount of exercise per week. According to WHO almost 40% of adults worldwide are overweight or obese. If the trend continues about one-fifth of the world’s population will be obese by 2025. Supporting metabolic health and weight management are key factors for maintaining long-term health and wellness.

Salacia Extract supports healthy carbohydrate metabolism

Extracts from the roots, stems and leaves of Salacia are used in Asia for the treatment of diabetes and associated risk factors and studies support their use for these conditions. By slowing down the breakdown and absorption of carbohydrates Salacia extract can potentially reduce the glycemic impact of food after a meal and contribute to a healthy insulin response.  

The B.I.G. Study Shows Salacia Supports a Healthy Insulin Response

OmniActive’s Blood Insulin Glucose (BIG) study was presented at Experimental Biology 2016 and demonstrated that a specific extract of Salacia – called OmniLean - reduces the glycemic impact of food and supports a healthy insulin response after a meal. Thirty-five healthy men and women, between the ages of 18 and 55, were enrolled in double-blind, placebo-controlled, crossover study. The test group ingested 200 mg, 300 mg, and 500 mg of OmniLean with a one-week washout between treatments.

All three doses significantly reduced blood insulin and glucose post carbohydrate load.  At 300 and 500 mg, OmniLean significantly reduced insulin area under the curve and suggests that reducing the early rise in blood glucose and insulin, Salacia extract (SE) may prevent the glucose spikes after a meal. The researchers also noted no significant adverse events at any dose of OmniLean.

The study confirms that OmniLean is a valuable resource in reducing postprandial rise in glucose and insulin. The results of the BIG study could have significant implications for people who are overweight and are at a higher risk for diabetes, heart disease, and other conditions associated with weight gain.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Copyright 2016 OmniActive Health Technologies Ltd.
OmniLean is a trademark of OmniActive health Technologies
1.       IDF. The IDF consensus worldwide definition of the metabolic syndrome
2.       Beltran-Sanchez H, et al. 2013
3.       Webmd.com
4.       WHO. WHO Diabetes Fact Sheet no 312. 2013
5.       Laslett LJ et al. J Am Coll Cardiology 2012